在阿尔茨海默病中微生物群-肠-大脑轴的失调及其通过益生菌补充剂的调节
Moira Marizzoni1, Elisa Mombelli1, Silvia Alboni2
1Biological Psychiatry Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Brain, behavior, and immunity
|October 15, 2025
概括
阿尔茨海默病 (AD) 患者表现出肠道微生物组的改变. 益生菌治疗部分改善了肠道健康,减少了炎症,这表明对AD管理的潜在益处.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 微生物群-肠-大脑轴 (MGBA) 越来越多地与阿尔茨海默病 (AD) 病理生理学有关.
- 益生菌在临床前阿尔茨海默病模型中表现有前途,但人类研究有限.
研究的目的:
- 在可能的AD (pAD) 中调查肠道微生物组 (GM) 差异,炎症和MGBA媒介.
- 评估12周益生菌治疗对pAD患者MGBA的影响.
主要方法:
- 招募了45名pAD患者和47名健康对照 (HC).
- 在pAD患者服用益生菌补充剂之前和之后评估便微生物群,肠道/血液炎症标志物和代谢物.
主要成果:
- 与HC相比,pAD患者表现出肠道炎症,改变的GM,托代谢和谷氨酸水平的变化.
- 在pAD患者中,益生菌补充剂减少了亲炎性介质,并增加了诸如丁酸盐之类的保护因素.
结论:
- 在AD患者中确认了MGBA变化.
- 益生菌可能通过调节转基因功能,而不仅仅是成分,有利于AD.
- 需要进一步的研究来验证临床相关性.
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822